Trial intelligence / Profile preview

Phase 3 study of peginterferon lambda-1a with or without daclatasvir versus peginterferon alfa-2a plus ribavirin in treatment-naive genotype 2 or 3 chronic hepatitis C

NL-OMON37644Phase 3Active, not recruiting

Sponsor

Bristol Myers Squibb

Start

Nov 2012

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1